<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03890042</url>
  </required_header>
  <id_info>
    <org_study_id>DAD</org_study_id>
    <nct_id>NCT03890042</nct_id>
  </id_info>
  <brief_title>Dienogest for Treatment of Adenomyotic Uteri</brief_title>
  <official_title>Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenomyosis is a common disease in women aged 40-50 years. It associates with dysmenorrhea
      and menorrhagia. Hysterectomy was considered the main treatment that could definitively cure
      this disease. Other treatment options are increasingly offered, including hormonal
      suppression with gonadotropin-releasing hormone agonists or danazol and endometrial ablation.
      However, deep adenomyosis responds weakly to the above treatment options, which are commonly
      not considered for long-term management because of the associated side effects.

      Dienogest is a progestin medication which is used in birth control pills and in the treatment
      of endometriosis and adenomyosis. Low-dose combined oral contraceptive (COC) pills have been
      widely used as the primary treatment for menorrhagia. COCs can also be used to induce
      endometrial atrophy and to decrease endometrial prostaglandin production, which can
      consequently improve menorrhagia and dysmenorrhea that are associated with adenomyosis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women who will improved from the pelvic pain measured by visual analogue scale</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine volume (cm 3 ) measure by ultrasound</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>Dienogest group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gynera group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest group</intervention_name>
    <description>VISANNE 2MG Tablet once daily</description>
    <arm_group_label>Dienogest group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gestodene-Ethinyl Estradiol</intervention_name>
    <description>Gynera tablet once daily</description>
    <arm_group_label>Gynera group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>ultrasound assessment of uterine volume</description>
    <arm_group_label>Dienogest group</arm_group_label>
    <arm_group_label>Gynera group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>visual analogue scale</intervention_name>
    <description>visual analogue scale for assessment of pain</description>
    <arm_group_label>Dienogest group</arm_group_label>
    <arm_group_label>Gynera group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 20-40 years

          -  Women with ultrasonographic evidence of adenomyosis

          -  Woman complains of vaginal bleeding or pelvic pain related to adenomyosis

        Exclusion Criteria:

          -  Women with a history of malignancy or histological evidence of endometrial hyperplasia

          -  any adnexal abnormality on ultrasound

          -  undiagnosed vaginal

          -  contraindication to receive Vissane or gynera .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women Health Hospital - Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed K ALi, MD</last_name>
      <phone>+201005537951</phone>
      <email>m_khairy2001@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 23, 2019</study_first_submitted>
  <study_first_submitted_qc>March 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>March 23, 2019</last_update_submitted>
  <last_update_submitted_qc>March 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Gestodene</mesh_term>
    <mesh_term>Femovan</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

